Financial conflicts of interest were present in the majority of cancer research reviewed in a study published July 15 in the Journal of the National Cancer Institute.
Researchers from New Haven, Conn.-based Yale University reviewed 36 studies published since 2015 to assess the prevalence of industry ties. Studies included in the analysis covered six areas: clinical trials, FDA meeting speakers, academic medical leaders, patient advocacy organizations, clinical guideline authors and practicing oncologists.
Here are three notes from the study:
- Financial conflicts of interest were present in 36.8% to 89% of cancer clinical trials, 65% to 92.1% of FDA meeting speakers and 76% to 100% of academic medical leaders.
- Financial conflicts of interest were present in 56% to 98.1% of patient advocacy organizations, 46.4% to 98.4% of clinical guideline and pathway authors and 24.7% to 100% of practicing oncologists.
- Industry sponsorship was found in 69% of clinical trials and among 61% of practicing oncologists, pooled across eligible studies.
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.